| Management target | Revenue FY30 |
|---|
| Revenue growth | 16.6% YoY in FY26. |
|---|---|
| Margins | EBITDA margin expansion from 18.5% to 19.4% over FY24-FY26. |
| Demand visibility | Strong domestic chronic demand and Europe/Canada pipeline. |
| Management confidence | High; citing 'stronger returns' and 'diversified growth platform'. |
Growth
FY26 revenue grew 16.6% YoY; PAT surged 33% YoY. EBITDA margins improved to 19.4% (+90 bps).
Outlook
Targets FY26-FY30 growth via obesity/oncology assets and R&D platforms like Biologics and ADCs.
Risks
Regulatory changes, supply chain challenges, and currency fluctuations in international markets.
Last quarter's promises, checked
Delivered
- Revenue growth low-to-mid-teens → Delivered 22.8% (= BEAT)
- Domestic growth return to double-digits → Delivered 10.2% (= BEAT)
- EBITDA margin expansion 70-100 bps → Delivered 19.7%, up 50 bps YoY but 120 bps vs FY24 (= BEAT)
Partly delivered
- Gross margin target 60% → Delivered 58.4% due to product mix (= PARTIAL)
Investor Presentation filed with BSE, NSE: EMCURE. Summary written with AI assistance from the document.
Emcure Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,950.60
- Market cap
- ₹37,005 Cr
- Revenue (annual)
- ₹9,204 Cr
- Net profit (annual)
- ₹924.4 Cr
- P/E (TTM)
- 36.6×Sector 50.4×
- Promoter holding
- 77.83%-0.04% QoQ
- FII holding
- 4.87%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Emcure Pharmaceuticals Ltd
All →Emcure Pharmaceuticals Annual General Meeting
Emcure Pharmaceuticals held its 45th Annual General Meeting on September 21, 2026. The meeting transacted ordinary and special business, including the approval of a final dividend.
Emcure Pharmaceuticals Employee Stock Options
Emcure Pharmaceuticals allotted 11,400 equity shares to employees following the exercise of vested options under the ESOP scheme. This increases the company's total issued share capital.
Emcure Pharmaceuticals Earnings Call Transcript: Key Takeaways
Emcure's Q1 FY27 results show strong performance driven by international markets and HIV (ARV) business, despite a transitional period in domestic operations following organizational restructuring and the acquisition of Sanofi and Roche portfolios.
- Call
- Guides 16% growth
Emcure Pharmaceuticals Investor Presentation: Key Takeaways
Emcure reported Q1 FY27 revenue growth of 22.8% YoY with PAT margins expanding 110 bps. Growth was driven by a 34.2% surge in International Business (58% of total revenue).
Emcure Pharmaceuticals Q1 FY27 Results: Net Profit ₹292.5 Cr, Up 36.2% YoY
Emcure Pharmaceuticals Ltd reported revenue from operations of ₹2,580 Cr (+22.8% YoY) and net profit of ₹292.5 Cr (+36.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹292.5 Cr · +36.2% YoY
Emcure Pharmaceuticals Earnings Call: Key Takeaways
Emcure surpassed $1 billion in revenue in FY26, growing 16.6% YoY with 41% adjusted PAT growth, driven by strong international performance and domestic expansion.